StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

1-[3-(Dimethylamino)propyl]-1-(4-fluorphenyl)-1,3-dihydroisobenzofuran-5-carbonitrilmonohydrobromid

Citalopram Hydrobromide

HCID 77995
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
59729-32-7
Standard-SMILES
Br.CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21
InChIKey
WIHMBLDNRMIGDW-UHFFFAOYSA-N
Summenformel
C20H22BrFN2O
Durchschnittliche Molmasse
405,3 g/mol
Monoisotopische Masse
404,08995

Überblick

Citalopram Hydrobromide is the orally bioavailable hydrobromide salt of the racemic bicyclic phthalene derivative citalopram with antidepressant activity. As a selective serotonin reuptake inhibitor (SSRI), citalopram selectively inhibits the CNS neuronal reuptake of serotonin, thereby potentiating serotonergic activity in the central nervous system (CNS). This agent has minimal effects on the CNS neuronal reuptake of norepinephrine (NE) and dopamine (DA).

Namen und Bezeichner

Bevorzugter Name
Citalopram Hydrobromide
IUPAC
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile;hydrobromide
Lokaler Name
1-[3-(Dimethylamino)propyl]-1-(4-fluorphenyl)-1,3-dihydroisobenzofuran-5-carbonitrilmonohydrobromid
Englischer Name
Citalopram hydrobromide
Summenformel
C20H22BrFN2O
Molmasse
405.3

Namen und Synonyme

citalopram hydrobromide59729-32-7Citalopram HBrElopramSeropramLu 10-171-BCitalopram (as hydrobromide)PaxoranPerrigo citalopramNSC-758684I1E9D14F36LU-10-171-B
Weitere Namen anzeigen
ERDOSTEINCitalopram hydrogen bromideCitalopram for system suitability CRSBonitrile HBrLu 10-171 HBrCitalopran HBrCitalopram-D4BrCitalopraM HBr APICitalopram HBr Salt
DTXSID408723441-(3-(dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile monohydrobromide5-Isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-, monohydrobromideRefChem:548341-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile monohydrobromide3-(5-cyano-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-1-yl)-N,N-dimethylpropan-1-aminium bromideCHEBI:3724DTXCID60819993

Datenbank-Bezeichner

CAS

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

Polarare Oberfläche (TPSA)
36,3 Ų
H-Brücken-Donoren
1
H-Brücken-Akzeptoren
4
Frei drehbare Bindungen
5
Schwere Atome
25
Formalladung
0
Komplexität
466

Experimentelle und physikochemische Eigenschaften

Human Drugs · 2 Einträge

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Physikochemische Eigenschaften

Schmelzpunkt
182 · 182-188°C
Flammpunkt
9 ℃ · 9℃
storage temp.
2 · 2-8°C
Löslichkeit
2 O: · H2O: soluble (sparingly)
Aggregatzustand
powder
Farbe
White
Wasserlöslichkeit
50 mM · Soluble to 50 mM in ethanol and to 10 mM in water
Merck
14 · 14,2318
Stabilität
Stable. Incompatible with strong oxidizing agents.
Major Application
clinical testing
InChI
1S/C20H21FN2O.BrH/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20;/h4-9,12H,3,10-11,14H2,1-2H3;1H

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Warning

H302 (96.5%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P270, P273, P301+P317, P330, P391, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 115 reports by companies from 15 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Regulatory InformationCitalopram hydrobromide: Does not have an individual approval but may be used under an appropriate group standard
Hazard Classes and CategoriesAcute Tox. 4 (96.5%)

Toxikologische Informationen

Treatment · 1 Eintrag

Establish and maintain an airway to ensure adequate ventilation and oxygenation. Gastric evacuation by lavage and use of activated charcoal should be considered. Careful observation and cardiac and vital sign monitoring are recommended, along with general symptomatic and supportive care. Due to the large volume of distribution of citalopram, forced diuresis, dialysis, hemoperfusion, and exchange transfusion are unlikely to be of benefit. There are no specific antidotes for Celexa. (L1712)

Exposure RoutesRapidly and well absorbed from the GI tract. Peak plasma concentrations occur within 4 hours of a single orally administered dose. Bioavailability is 80% following oral administration. Food does not affect absorption.
Toxicity Summary · 1 Eintrag

Chemie und Industrie

Pharmakologische Informationen

Metabolism/Metabolites · 1 Eintrag

Citalopram is metabolized mainly in the liver via <i>N</i>-demethylation to its principle metabolite, demethylcitalopram. Other metabolites include didemethylcitalopram, citalopram <i>N</i>-oxide, and a deaminated propionic acid derivative. However, the predominant entity in plasma is unchanged citalopram. Cytochrome P450 (CYP) 3A4 and 2C19 isozymes appear to be principally involved in producing demethylcitalopram. Demethylcitalopram appears to be further <i>N</i>-demethylated by CYP2D6 to didemethylcitalopram. Citalopram metabolites possess little pharmacologic activity in comparison to their parent compound and do not likely contribute to the clinical effect of the drug. Route of Elimination: 12-23% of an oral dose of citalopram is recovered unchanged in the urine, while 10% of the dose is recovered in the feces. Half Life: 35 hours

FDA Pharmacological Classification · 2 Einträge

CITALOPRAM HYDROBROMIDE

Serotonin Reuptake Inhibitor [EPC]; Serotonin Uptake Inhibitors [MoA]

MeSH Pharmacological Classification · 2 Einträge

A structurally and mechanistically diverse group of drugs that are not tricyclics or monoamine oxidase inhibitors. The most clinically important appear to act selectively on serotonergic systems, especially by inhibiting serotonin reuptake.

Compounds that specifically inhibit the reuptake of serotonin in the brain.

Verwendung und Herstellung

Uses · 1 Eintrag

For the treatment of depression. Unlabeled indications include: treatment of mild dementia-associated agitation in nonpsychotic patients, smoking cessation, ethanol abuse, obsessive-compulsive disorder (OCD) in children, and diabetic neuropathy.

Anwendungen · 2 Einträge

Zugehörige Reaktionen

23
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 489491
HRID 489491als Produkt
Reaktionsgleichung von HRID 496867
HRID 496867als Produkt
Reaktionsgleichung von HRID 526806
HRID 526806als Edukt
Reaktionsgleichung von HRID 526807
HRID 526807als Edukt
Reaktionsgleichung von HRID 526808
HRID 526808als Edukt
Reaktionsgleichung von HRID 526809
HRID 526809als Edukt
Reaktionsgleichung von HRID 526810
HRID 526810als Edukt
Reaktionsgleichung von HRID 840347
HRID 840347als Produkt
ZurückSeite 1 von 3

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
59729-32-7
PubChem CID
77995
DTXSID
DTXSID40872344
ChEMBL
CHEMBL1200781
UNII
I1E9D14F36
EC Number
261-890-6
InChIKey
WIHMBLDNRMIGDW-UHFFFAOYSA-N
SMILES
Br.CN(C)CCCC1(OCc2cc(ccc12)C#N)c3ccc(F)cc3
CAS Datenbank
59729 · 59729-32-7(CAS DataBase Reference)

The antidepressant, antiobsessive-compulsive, and antibulimic actions of citalopram are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. Citalopram blocks the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 5HT<sub>1A</sub> autoreceptors. SSRIs bind with significantly less affinity to histamine, acetylcholine, and norepinephrine receptors than tricyclic antidepressant drugs.

Signs and Symptoms · 1 Eintrag

Symptoms most often accompanying citalopram overdose, alone or in combination with other drugs and/or alcohol, included dizziness, sweating, nausea, vomiting, tremor, somnolence, and sinus tachycardia. In more rare cases, observed symptoms included amnesia, confusion, coma, convulsions, hyperventilation, cyanosis, rhabdomyolysis, and ECG changes (including QTc prolongation, nodal rhythm, ventricular arrhythmia, and very rare cases of torsade de pointes). Acute renal failure has been very rarely reported accompanying overdose. Withdrawal symptoms include flu-like symptoms, insomnia, nausea, imbalance, sensory changes and hyperactivity.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6 Einträge

Drug Induced Liver Injury Rank (DILIrank 2.0)

Citalopram hydrobromide

vLess-DILI-concern

7

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Sicherheitsdaten

wgk
3
ridadr
3249
hs_code
29329990
RTECS-Nr.
NP6313500
risk_code
11-23/24/25-39/23/24/25-22
hazard_code
F,T
safety_code
7-16-36/37-45-24/25
hazard_class
6.1(b)
packing_group
III
Speicherklasse
3 - Flammable liquids
Hazard Classifications
Acute Tox. 3 DermalAcute Tox. 3 InhalationAcute Tox. 3 OralFlam. Liq. 2STOT SE 1

BeschreibungCitalopram (hydrobromide) (Item No. 23252) is an analytical reference material categorized as an antidepressant. This product is intended for use in analytical forensic applications. This product is also available as a general research tool .

VerwendenCitalopram hydrobromide has been used:to examine its effects onsirtmRNA and mammalian sirtuins (SIRT) expression in miceto monitor body temperature and antidepressant-like behavioral responses in the forced swim test for ratsfor 5-hydroxytryptamine (5-HT) competition uptake assays

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

ButyllithiumMagnesiumThionyldichloridChlor(1-methylethyl)magnesiumKohlenstoffdioxid(tert-Butyl)methyletherSchwefelsaeurediamid1,3-Dihydroisobenzofuran